欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
M059J人脑恶性胶质母细胞瘤细胞(STR鉴定)
英文名:M059J
货号:ZQ1196
价格:¥询价
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

M059J人脑恶性胶质母细胞瘤细胞(STR鉴定)

¥询价
+
=

细胞套餐惊爆价

¥550
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

M059J人脑恶性胶质母细胞瘤细胞

货号

ZQ1196

产品介绍

M059J 是从一名 33 岁男性恶性胶质母细胞瘤患者的大脑中分离出来的胶质细胞。这些细胞系提供了有用的模型系统,可用于研究 DNA 蛋白激酶在涉及 DNA 损伤识别和修复的细胞和分子过程中的作用。它可用于神经科学研究。

M059J 细胞缺乏 DNA 依赖性蛋白激酶活性,而 M059K 细胞表达正常水平的 DNA 依赖性蛋白激酶。M059J 细胞对电离辐射的敏感性比 M059K 细胞高约 30 倍。M059J 细胞比 M059K 细胞对博来霉素、N,N-双(2-氯乙基)-N-亚硝基脲和氮芥的细胞毒性作用更敏感。M059J 细胞缺乏 DNA 双链断裂修复能力。这些细胞的神经胶质原纤维酸性蛋白 (GFAP) 呈阴性。

种属

性别/年龄

男,33岁

组织

疾病

胶质母细胞瘤

细胞类型

肿瘤细胞系

形态学

成纤维细胞样

生长方式

贴壁

倍增时间

***

培养基和添加剂

DMEM/F12(中乔新舟 货号:ZQ-600 +10%胎牛血清(中乔新舟  货号:ZQ500-A+1%P/S(中乔新舟  货号:CSP006+1% Sodium Pyruvate 100 mM Solution(中乔新舟  货号:CSP003+1%Non-essential Amino Acids, 100X (中乔新舟  货号:CSP008

推荐完全培养基货号

ZM1196

生物安全等级

BSL-1

培养条件

95%空气,5%二氧化碳;37℃

STR位点信息

Amelogenin X (PubMed=25877200)

                        X,Y (ATCC=CRL-2366; Cosmic-CLP=949094)

CSF1PO 10 (PubMed=25877200)

                 10,12 (ATCC=CRL-2366; Cosmic-CLP=949094)

D2S1338 20,24

D3S1358 14 (PubMed=25877200)

                   14,15 (ATCC=CRL-2366)

D5S818 11,12 (ATCC=CRL-2366; Cosmic-CLP=949094)

                 12 (PubMed=25877200)

D7S820 10 (PubMed=25877200)

                 10,12 (ATCC=CRL-2366; Cosmic-CLP=949094)

D8S1179 15

D13S317 14

D16S539 10,12

D18S51 15,19

D19S433 14

D21S11 30,31.2

FGA 20

Penta D 12,13

Penta E 7

TH01 9.3

TPOX 8

vWA 17

抗原表达/受体表达

***

基因表达

***

保藏机构

ATCC; CRL-2366

BCRC; 60382

BCRJ; 0151

供应限制

仅供科研使用

货号

ZQ1196

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用

PubMed=8316628; DOI=10.2307/3578196
Allalunis-Turner M.J., Barron G.M., Day R.S. 3rd, Dobler K.D., Mirzayans R.
Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs.
Radiat. Res. 134:349-354(1993)

PubMed=7494872; DOI=10.2307/3578948
Allalunis-Turner M.J., Zia P.K.Y., Barron G.M., Mirzayans R., Day R.S. 3rd
Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line.
Radiat. Res. 144:288-293(1995)

PubMed=10629611; DOI=10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2
Hoppe B.S., Jensen R.B., Kirchgessner C.U.
Complementation of the radiosensitive M059J cell line.
Radiat. Res. 153:125-130(2000)

PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2
Anderson C.W., Allalunis-Turner M.J.
Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8.
Radiat. Res. 154:473-476(2000)

PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2
Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M., Allalunis-Turner M.J.
Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J.
Radiat. Res. 156:2-9(2001)

PubMed=12105990; DOI=10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2
Tsuchida R., Yamada T., Takagi M., Shimada A., Ishioka C., Katsuki Y., Igarashi T., Chessa L., Delia D., Teraoka H., Mizutani S.
Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast.
Radiat. Res. 158:195-201(2002)

PubMed=18757420; DOI=10.1158/0008-5472.CAN-08-0545; PMCID=PMC2528059
Burdak-Rothkamm S., Rothkamm K., Prise K.M.
ATM acts downstream of ATR in the DNA damage response signaling of bystander cells.
Cancer Res. 68:7059-7065(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号